Innovation in medicines: adapting for the future

This content relates to the following topics:

Never has scientific research looked as promising as it does now, with new exciting possibilities for tackling diseases through the development of innovative medicines. The process, from research to use, takes several years and requires the close collaboration of many stakeholders. What is the role of each part of the system – from industry researcher, through the regulating medicines authorities, to NHS clinicians and patients? And, given their differing perspectives, how do these different parts of the system view the future of innovation in research, medicines and the NHS?

This event explored the process of developing new medicines and discussed what access and uptake entail, with experts on hand to answer questions and clarify how the system works at the moment.  We discussed the best way forward to make the most of innovation, while maintaining patient safety and clinical standards.

Please note, this event was pre-recorded and our speakers were watching along and answered the most popular questions during the livestream on 21st September.  The content was pre-recorded before the September 2021 government reshuffle.


This event was held in partnership with the Association of the British Pharmaceutical Industry (ABPI). If you're interested in partnering with us on an online event please email Kieran Cornwell




Paula Head (Chair)

Senior Fellow, The King’s Fund


Lord Bethell of Romford

Former Parliamentary Under Secretary of State (Minister for Innovation)

This content was pre-recorded before the September 2021 government reshuffle


Paul Catchpole

Value and Access Policy Director, Association of the British Pharmaceutical Industry (ABPI)


Nick Meade

Joint Interim Chief Executive and Director of Policy, Genetic Alliance UK


Sharmila Nebhrajani OBE

Chairman, National Institute for Health and Care Excellence


Dr Olivia Rossanese

Interim Director of the Cancer Research UK Cancer Therapeutics Unit and Interim Head of the Division of Cancer Therapeutics, The Institute of Cancer Research